Sort by
Refine Your Search
-
for (1) engineering BPAN genetic variants into cell lines; (2) developing cellular assays including of autophagy function and cellular survival; (3) working with the Stanford high throughput drug screening
-
biochemistry and biophysics directed at the discovery and development of new antibacterial therapeutics targeting difficult-to-treat bacteria. More broadly and coupled to drug discovery, we define the molecular
-
laboratory of Stephen Skirboll, MD and Albert Wong, MD, in the Department of Neurosurgery at Stanford University School of Medicine and the VA Palo Alto. We are interested in developing immunotherapies
-
The Stanford Abdominal Diffusion Group is seeking thoughtful, motivated and collaborative postdoctoral fellows to join a growing team developing motion-robust multi-shot DWI methods for liver, pancreatic, and
-
: General Surgery Postdoc Appointment Term: This is a two-year fellowship position that begins on July 1, 2025 and ends on June 30, 2027. Appointment Start Date: July 1, 2025 Group or Departmental Website
-
environment for all members of the university community and its property. To that end, new staff hires must successfully pass a background check prior to starting work at Stanford University. Required
-
—to address critical sustainability and climate resilience challenges. Your primary focus will be on developing, refining, and deploying innovative genetic engineering tools for CRISPR-Cas9 delivery. Key
-
Substitution in the Blind; Ocular Structures and Physiology; MR Engineering and Methods Development for the Visual System. MRI experiments will mainly be conducted at research centers at the Stanford campus and
-
, with special emphasis on autism, depression, and addiction. There are ample opportunities for career development and clinical exposure based on candidate interest. Required Qualifications: The ideal
-
immunosuppression, akin to PDL1-PD1 interactions. In collaboration with Carolyn Bertozzi’s group, we are developing bifunctional proteins that include an antibody to cell surface cancer proteins (e.g. PSMA, CA9) and